免疫检查点抑制剂相关心包疾病研究进展  

Research advances in pericardial diseases associated with immune checkpoint inhibitors

作　　者：张舟 罗丹 谭梦琴 王福军 ZHANG Zhou;LUO Dan;TAN Mengqin;WANG Fujun(Department of Cardiology,Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital,Jishou Hunan 416000;Emergency Medical Center,Hunan University of Medicine General Hospital,Huaihua Hunan 418000;Cardiac Center,Geriatric Hospital of Hainan,Haikou Hainan 571100,China)

机构地区：[1]湘西土家族苗族自治州人民医院心内科,湖南吉首416000 [2]湖南医药学院总医院急救医学中心,湖南怀化418000 [3]海南省老年病医院心脏中心,海南海口571100

出　　处：《实用心电学杂志》2024年第6期553-556,共4页Journal of Practical Electrocardiology

基　　金：湖南省卫生健康委员会科研资助项目(202203014682);中国药文化研究会医药科教分会科研一般项目(2024KXJS0004)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)能阻断肿瘤的免疫逃逸,已被广泛应用于多种恶性肿瘤的治疗,但其导致的免疫相关不良事件也随之增多。心包疾病是常见的ICIs相关心血管不良反应,在急性期致死率较高。本文介绍了ICIs相关心包疾病的流行病学、致病机制、临床特点、治疗原则等方面的研究进展,以提高临床医生对该病的认识。Immune checkpoint inhibitors(ICIs) have been widely applied in the clinical treatment of various malignant tumors by blocking the tumor immune escape.However,it is followed by increasing immune-related adverse events caused by ICIs.As common ICIs-related cardiovascular adverse reactions,pericardial diseases lead to a relatively high mortality at the acute phase.This article introduces the research progress in recent years on the epidemiology,pathogenesis,clinical characteristics,and treatment principles of ICIs-related pericardial diseases,in order to deepen the clinicians' understandings of this disease.

关 键 词：免疫检查点抑制剂 心包疾病 心血管毒性 肿瘤免疫疗法 

分 类 号：R967[医药卫生—药理学] R542.1[医药卫生—药学]